Repression of Mitogen-Activated Protein Kinase (MAPK) Phosphatase-1 by Anthracyclines Contributes to their Anti-apoptotic Activation of p44/42-MAPK

George W. Small[1], Sivagurunathan Somasundaram[1,*], Dominic T. Moore[1], Yue Y. Shi[1], and Robert Z. Orlowski[1,2]

[1]The Lineberger Comprehensive Cancer Center and [2]Department of Medicine, Division of

Hematology/Oncology, University of North Carolina at Chapel Hill,

Chapel Hill, North Carolina 27599-7295

Running Title: Anthracyclines activate p44/42-MAPK by repressing MKP-1

Corresponding author: Dr. Robert Z. Orlowski, University of North Carolina at Chapel

Hill, 22-003 Lineberger Comprehensive Cancer Center, CB # 7295/Mason Farm Road, Chapel

Hill, NC 27599-7295; Telephone: 919-966-9762, FAX: 919-966-8212, E-mail:

R_Orlowski@med.unc.edu

Manuscript statistics: Number of text pages: 23; Number of tables: 1; Number of figures:

7; Number of references: 39; Number of words in the *Abstract*: 233; Number of words in the

Introduction: 719; Number of words in the *Discussion*: 1011

Nonstandard abbreviations: CA, constitutively active; CMV, cytomegalovirus; DAPI,

4,6-diamidino-2-phenylindole; EGF, epidermal growth factor; ERK, extracellular-signal-

regulated kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HA, hemagglutinin;

HSC, heat shock cognate protein; LCCC TCF, Lineberger Comprehensive Cancer Center Tissue

Culture Facility; luc, luciferase; MAPK, mitogen-activated protein kinase; MEFs, mouse embryo

fibroblasts; MEK, mitogen activated protein kinase kinase; MEM, Modified Eagle's Medium;

MKP, mitogen-activated protein kinase phosphatase; OA, okadaic acid; PD, PD 98059; PP1,

phosphoprotein phosphatase-1; PP2A, phosphoprotein phosphatase-2A; RSK, ribosomal protein

S6 kinase; RT-PCR, reverse transcription polymerase chain reaction; siRNA, small interfering

RNA

Recommended section assignment: Chemotherapy, Antibiotics, & Gene Therapy

Abstract

Anthracyclines are commonly used chemotherapeutics, and in some models enhance p44/42-mitogen-activated protein kinase (MAPK) pathway signaling by effects on upstream kinases. To evaluate the impact of anthracyclines on p44/42-MAPK in breast cancer, A1N4-*myc* human mammary, and BT-474 and MDA-MB-231 breast carcinoma cells were studied. Treatment with doxorubicin or epirubicin resulted in increased phospho-p44/42-MAPK levels in a time- and concentration-dependent manner. This was associated with p44/42 activation, as reflected by increased p90 ribosomal protein S6 kinase and Bad phosphorylation. Activation of p44/42 appeared to be anti-apoptotic, since MAPK stimulation with epidermal growth factor or a dominant-positive p42 construct inhibited apoptosis. Modest activation of the upstream MAPK kinase MEK was noted under some conditions, but inhibition of MEK did not abolish p44/42 activation, suggesting contribution from another mechanism. Anthracyclines were found to decrease expression of MAPK phosphatase-1 (MKP-1) both *in vitro* and *in vivo*. MKP-1 mRNA levels were decreased in anthracycline-treated cells, and transcription from the MKP-1 promoter was repressed. Inhibition of MKP-1 expression through the use of small interfering RNAs decreased the ability of anthracyclines to induce phospho-p44/42. Wild-type mouse embryo fibroblasts (MEFs) treated with doxorubicin showed increased phospho-p44/42-MAPK levels, but MEFs from MKP-1 heterozygous and homozygous knockout mice had blunted p44/42 activation. These studies support the ability of anthracyclines to activate anti-apoptotic p44/42-MAPK phosphorylation in breast cancer, and indicate that this occurs in part through the novel mechanism of repression of MKP-1 transcription.

Many drugs used in cancer therapy have pleiotropic effects, and while they activate apoptosis they can also activate anti-apoptotic signal transduction pathways that promote survival, possibly limiting their own anti-tumor efficacy. One notable example of this is the nuclear factor κB pathway, whose activation by many DNA damaging agents results in enhanced transcription of Bcl-2 homologues such as Bcl-x_L (recently reviewed by Orlowski and Baldwin, 2002). Another is the p44/42-mitogen activated protein kinase (MAPK) pathway whose activation, with some exceptions, generally results in an increase in the threshold for cell death (reviewed by Dent and Grant, 2001). The survival signals induced by p44/42 activation may in part be communicated through phosphorylation of p90 ribosomal protein S6 kinase (RSK) and then Bad, which in its phosphorylated form cannot translocate to mitochondria and form pro-apoptotic heterodimers with Bcl-x_L (Bonni et al., 1999; Scheid et al., 1999). Anthracycline-based anti-tumor antibiotics have been described to activate p44/42-MAPK in some cell systems. These include primary rat ventricular myocytes (Adderley and Fitzgerald, 1999; Zhu et al., 1999), neuroblastoma cells (Guise et al., 2001), rat hepatoma cells (Kim et al., 2001), human cervical carcinoma cells (Yeh et al., 2002), and monoblasts (Mas et al., 2003). As a result of the cardiotoxic effects of anthracyclines the consequence of this activation on apoptosis has best been studied in cardiac myocytes, where it seems to be protective since MEK blockade increased cell death (Zhu et al., 1999). In other models, however, p44/42 activation may be pro-apoptotic, in that MEK blockade reduced apoptosis of SK-N-SH cells (Guise et al., 2001), and in still others such blockade had no impact on programmed cell death (Kim et al., 2001; Yeh et al., 2002). While anthracyclines are used in a variety of human cancers, one of their more common applications is in the therapy of patients with breast cancer. Signaling by the *erb*B receptor

tyrosine kinase family, which occurs in part through p44/42, has been implicated in the development and progression of breast cancer, and elevated expression of *c-erb*B-2 (HER-2/neu) and the epidermal growth factor (EGF) receptor (*c-erb*B-1) is a poor prognostic sign (reviewed by Dickson and Lippman, 1995). Elevated activity of p44/42-MAPK alone, also referred to as the extracellular signal-regulated kinases (ERK-1/2), has been suggested to have prognostic significance for survival of breast cancer patients (Mueller et al., 2000). The impact of anthracyclines on p44/42-MAPK in breast cancer, or the influence of any activity changes on apoptosis, however, has not been well studied.

The mechanism by which anthracyclines activate p44/42 may involve generation of oxygen free radicals, in that scavengers such as DMSO, catalase, and N-(2-mercaptopropionyl)-glycine suppress phospho-ERK levels (Zhu et al., 1999). Once generated these radicals seem then to activate the Ras-Raf-MEK-MAPK pathway, since dominant negative Ras (Zhu et al., 1999) and Raf-1 constructs (Zhu et al., 1999; Mas et al., 2003), as well as pharmacologic inhibitors of Raf (Mas et al., 2003) and MEK (Zhu et al., 1999; Yeh et al., 2001; Mas et al., 2003) suppressed ERK activation. Raf-1 stimulation may also be mediated through phosphatidylcholine-derived diacylglycerol production, and phosphoinositide-3 kinase stimulation products that converge toward protein kinase C zeta (Mas et al., 2003). Since free-radical scavengers do not completely block ERK activation, however (Mas et al., 2003), the possibility that other mechanisms contribute needs to be considered.

In the current report we present data demonstrating that anthracycline treatment of breast epithelial and breast carcinoma cells resulted in a time- and concentration-dependent activation of signaling through ERK-1/2. This increase appeared to be anti-apoptotic, in that stimulation of p44/42 signaling in combination with anthracyclines protected cells from apoptosis. Though

modest activation of MEK by anthracyclines was observed in some experiments, others did not

demonstrate this finding, and MEK inhibition did not abolish p44/42 activation. Anthracyclines

were found to decrease expression of the MAPK phosphatase MKP-1 at both the protein and

mRNA levels, and to specifically repress transcription from the MKP-1 promoter. Cells in which

MKP-1 expression was decreased through the use of small interfering (si) RNAs, and cells

derived from MKP-1 knockout mice, had blunted activation of p44/42 in response to

doxorubicin. These studies support the hypothesis that anthracyclines activate the p44/42-MAPK

pathway in breast epithelial and carcinoma cells, that this activation may inhibit their own anti-

tumor activity, and that this occurs in part through repression of transcription of MKP-1.

Methods

Materials. Doxorubicin was from Sigma-Aldrich Co. (St. Louis, MO), while

epirubicin (Ellence™; Pharmacia & Upjohn; Peapack, NJ) was from the University of North

Carolina at Chapel Hill Memorial Hospital Pharmacy, and pegylated liposomal doxorubicin

(Doxil®) was from Ortho Biotech Products, L.P. (Bridgewater, NJ). Phosphatase inhibitors

deltamethrin, nodularin, and okadaic acid were from Calbiochem (San Diego, CA), as was the

MEK inhibitor PD 98059, while sodium orthovanadate was from Sigma-Aldrich Co. The

protease cocktail Complete™ was from Roche Applied Science (Indianapolis, IN), while PMSF

was from Fisher Scientific (Fair Lawn, NJ). Stock solutions were prepared in isopropanol for

PMSF, Dulbecco's PBS (from the Lineberger Comprehensive Cancer Center Tissue Culture

Facility (LCCC TCF)) for sodium orthovanadate, or DMSO for all others, and stored at -20°C.

These reagents were used at concentrations indicated in the text, with a final vehicle

concentration that did not exceed 0.5% (v/v). All other chemicals, unless otherwise indicated,

were obtained from Fisher Scientific.

Cell lines and cell culture. A1N4-*myc* cells were grown in Richter's Modified Eagle's

Medium (MEM) with insulin, gentamicin, and 20 mM Hepes (LCCC TCF), and further

supplemented with human recombinant EGF at 10 ng/ml, 9% fetal bovine serum, penicillin G

sodium at 100 units/ml, streptomycin sulfate at 100 μg/ml (these reagents from GibcoBRL;

Grand Island, New York), and hydrocortisone (Sigma Chemical Co.). MDA-MB-231 and BT-

474 human breast carcinoma cells (LCCC TCF) were grown in Richter's MEM as above except

without EGF and hydrocortisone. Mouse embryo fibroblasts from heterozygous and homozygous

MKP-1 knockout mice (Dorfman et al., 1996), as well as wild-type controls, generously

provided by Dr. Naomi Laing and the Bristol Myers Squibb Research Institute (Princeton, NJ),

were cultured in Dulbecco's MEM. All cells were propagated in incubators providing a

humidified atmosphere with 5% CO_2 in air.

Western blotting. Adherent cells were detached by exposure to trypsin (GibcoBRL),

counted using a hemacytometer (Hausser Scientific; Horsham, PA), and 2×10^6 cells were

seeded onto 60 mm Falcon 3002 tissue culture plates (Becton Dickinson Labware; Lincoln Park,

NJ) in complete medium. These cells were allowed to reattach overnight, and subjected to

conditions described in the text along with the addition of fresh medium. At the completion of an

experiment all plates were placed on ice, washed with 5 ml of ice-cold PBS, and collected by

scraping into eukaryotic lysis buffer as described previously (Orlowski et al., 2002). Relative

protein concentrations of each sample were determined using the BCA protein assay kit (Pierce

Chemical Co.; Rockford, IL). Equivalent protein amounts were subjected to Western blotting,

and immunoreactive bands were detected as described (Orlowski et al., 2002). For repeated

analyses of the same filter, blots were stripped for 45 minutes using Western Re-Probe (Geno

Technology, Inc.; St. Louis, MO) following the manufacturer's specifications.

Activation status of the p44/42-MAPKs was determined using murine monoclonal

antibodies recognizing active, dually phosphorylated p44/42 (Thr202/Tyr204), with rabbit

p44/42 antibodies used as loading controls. The activation status of the mitogen activated protein

kinase kinase (MEK) was determined using rabbit polyclonal antibodies recognizing active,

dually phosphorylated MEK-1/2 (Ser217/Ser221), with rabbit MEK-1/2 antibodies used as

loading controls. p90 RSK phosphorylation status was evaluated using rabbit polyclonal

antibodies recognizing active, dually phosphorylated (Thr359/Ser363) RSK, and Bad

phosphorylation status was evaluated using a murine monoclonal antibody recognizing phospho-Ser112-Bad (all from Cell Signaling Technology, Inc.). Total RSK levels were determined by Western blotting with a murine monoclonal anti-RSK antibody (BD Biosciences; Lexington, KY), while Bad levels were evaluated with a rabbit polyclonal anti-Bad antibody (Cell Signaling Technology, Inc.). Expression levels of the MKP-1 phosphatase were determined with the rabbit polyclonal C-19 antibody to MKP-1 (Santa Cruz Biotechnology, Inc.). Additional loading controls were provided by a rat monoclonal anti-HSC-70 antibody (StressGen Biotechnologies Corp.; Victoria, BC, Canada).

To quantify protein bands autoradiographs were scanned with an Agfa Duoscan T2500 scanner (Agfa Corp.; Ridgefield Park, NJ) into Adobe Photoshop 5.0 (Adobe Systems, Inc.; San Jose, CA), and densitometry was performed using NIH Image version 1.61.

Apoptosis assays. For apoptosis experiments cells were seeded onto Costar 3595 96-well plates (Corning Inc.; Corning, NY) at a density of $1x10^4$ cells/well. Fresh medium was added containing the agents whose impact was being tested, and cells were analyzed for apoptosis using the Cell Death Detection ELISA[PLUS] kit (Roche Molecular Biochemicals; Indianapolis, IN) according to the manufacturer's specifications. The enhancement of apoptosis was calculated in relation to parallel control cells which received vehicle alone, and tabulated in KaleidaGraph version 3.0.1 (Synergy Software; Reading, PA). Mean percentages and standard errors of the mean were then calculated. For experiments with EGF, cells were treated for 18 hours with 0.75 μM anthracyclines in the absence or presence of EGF at 15 ng/ml. Dominant positive constructs, as well as controls, were treated with 1 μM doxorubicin for 18 hours.

Cloning and cell line preparation. The hyperactive allele of ERK-2 (D319N) tagged

with hemagglutinin (HA) was cloned into the vector pLPCX (Clontech Laboratories Inc.; Palo

Alto, CA) as described (Orlowski et al., 2002). Briefly, to prepare A1N4-*myc*- and MDA-MB-

231-based cell lines, which must be transduced with retroviral-based vectors, the indicated ERK

clones were transfected into AmphoPack™-293 cells using the CalPhos™ Mammalian

Transfection Kit (both from Clontech Laboratories Inc.) according to the manufacturer's

specifications. Supernatants with retroviral particles were collected and used to infect the target

cells in medium containing 8 μM Polybrene. Selection was performed in media containing

puromycin (Calbiochem-Novabiochem Corp.) and screening of clones was performed using a

murine anti-HA monoclonal antibody (F7; Santa Cruz Biotechnology, Inc.). Stable cell lines in

BT-474 cells containing this construct were prepared by direct transfection using the

GenePORTER™ reagent according to the manufacturer's specifications (Gene Therapy Systems;

San Diego, CA), followed by selection and screening as described above.

Immunofluorescence. The *in vivo* impact of anthracycline therapy was evaluated

using a BT-474-based xenograft model system developed as described previously

(Somasundaram et al., 2002). All experiments were performed under a protocol approved by the

Institutional Animal Care and Use Committee. Three mice each were assigned to the two

treatment groups, and received either an injection of vehicle, or a single injection of pegylated,

liposomal doxorubicin (Doxil®) at 2 mg/kg. Twenty four hours later the groups were euthanized

using guidelines established by the American Veterinary Medical Association's Panel on

Euthanasia. Tumors were then excised, and fixed in Tissue-Tek® O.C.T. (Sakura Finetek U.S.A.,

Inc.; Torrance, CA) while freezing in liquid nitrogen. For detection of phospho-ERK-1/2 and

MKP-1 sections were washed in 6:1 methanol:water, air dried, and after blocking they were

stained using the antibodies identified above. Secondary antibodies consisted of either cy3-

flourescent conjugated goat anti-mouse antibody or fluorescein-conjugated goat anti-rabbit

antibody (Chemicon International). Sections were incubated for 15 min., washed in PBS, and

mounted with a 4,6-diamidino-2-phenylindole (DAPI) nuclear stain (Vector Laboratories;

Burlingame, CA). Slides were visualized using an ultraviolet Zeiss Axioplan fluorescence

microscope (Carl Zeiss Optical, Inc.; Chester, VA). Separate photographs were taken with

appropriate filters for blue nuclear staining and red ss-DNA staining, overlayed using Adobe

Photoshop software, and displayed as a fusion image at 10x magnification.

Reverse transcription polymerase chain reaction (RT-PCR).   Cell cultures were

treated as above for Western blotting, after which total RNA was isolated using RNeasy

(QIAGEN Inc.; Valencia, CA) according to the manufacturer's specifications. RNA yields were

assessed by spectrophotometric analysis, and specific gene expression was examined using the

Access RT-PCR System (Promega Corporation; Madison, WI). Briefly, first-strand cDNAs were

synthesized starting with 10 ng of total RNA from each sample using Avian Myeloblastosis

Virus Reverse Transcriptase at 48°C for 45 minutes with the appropriate primers. Second-strand

cDNA synthesis and amplifications were then performed with *Tfl* DNA Polymerase using an

automated thermal cycler (Perkin-Elmer 480; Norwalk, CT) set to the following parameters:

94°C for 2 min (1 cycle); 94°C for 30 seconds, 57°C for 2 min, 68°C for 2 min (40 cycles),

and 68°C for 7 min (1 cycle). The primers used for MKP-1 were 5'-

GCTGTGCAGCAAACAGTCGA-3' (upstream), 5'-CGATTAGTCCTCATAAGGTA-3'

(downstream) (Kojima et al., 2000); for *c-myc* 5'-CTGGTGCTCCATGAGGAG-3' (upstream),

5'-AGGTGATCCAGACTCTGAC-3' (downstream); and for glyceraldehyde-3-phosphate

dehydrogenase (GAPDH) 5'-CCATGGAGAAGGCTGGGG-3' (upstream), 5'-

CAAATGTGTCATGGATGACC-3' (downstream). Samples of the reaction products were

then subjected to electrophoresis on a 5% polyacrylamide gel (19:1 acrylamide:

bisacrylamide ratio) in 1% Tris-borate-EDTA running buffer at 50V, visualized by ethidium

bromide staining, and images were acquired using the FluorChem™ 8000 imaging system with

AlphaEaseFC software™ (Alpha Innotech Corp.; San Leandro, CA). Densitometry was

performed using NIH Image version 1.61. Statistical analysis of the results was performed using

the van der Waerden two sample test, and all significant results were confirmed using the

Wilcoxon signed-rank test. A *P* value of <0.05 was considered statistically significant.

Luciferase assays.　　　The pGL3-MKP-1-luc reporter plasmid containing the MKP-1

promoter in a genomic fragment spanning positions –2975 to +247 cloned in front of the firefly

luciferase (luc) gene was kindly provided by Dr. Yusen Liu (National Institutes of Health;

Baltimore, MD) (Li et al., 2001). pHRL-CMV containing the cytomegalovirus (CMV)

immediate early enhancer/promoter cloned in front of the *Renilla* luciferase gene was from

Promega Corporation. Stable cell lines containing these reporter vectors were constructed by co-

transfection of BT-474 cells with either pGL3-MKP-1-luc and pLPCX (Clontech Laboratories

Inc.; Palo Alto, CA), or pHRL-CMV and pLPCX as described above.

　　Luciferase reporter assays were conducted by seeding these cells at 2×10^4 per well

into Costar 3595 96-well tissue culture plates, which were then allowed to recover overnight.

Following the indicated treatments, cells were harvested using the Promega Dual-Luciferase[®]

Reporter Assay System according to the manufacturer's specifications. Cell lysates were

transferred to an opaque 96-well plate and luciferase activity was measured using an Lmax

microplate luminometer with SOFTmax PRO 1.1L software (Molecular Devices; Sunnyvale,

CA) set for an injection of 75 μl of detection reagent and a 2-second pre-read delay, followed

by a 20-second signal integration time. MKP-luciferase activity was then normalized against

pHRL (CMV-luciferase) activity and expressed relative to an untreated control. Statistical

analysis of the results was performed as described above.

Silencing of MKP-1.　　　　　The human MKP-1 gene was analyzed to identify possible

sequences for small interfering (si) RNAs using the siRNA Target Finder and Design Tool

(Ambion Inc.; Austin, Texas). Potential targets were evaluated by BLAST sequence analysis,

and for those which were specific for MKP-1 complementary oligonucleotides with overhanging

Apa I and EcoR I restriction sites were synthesized. These were cloned into p*Silencer* 1.0-U6

(Ambion Inc.) that had been linearized with Apa I and EcoR I, and the resulting vectors were co-

transfected with pLPCX into BT-474 cells and selected as described above. Clones were

screened by Western blotting to identify those that had lowered basal levels of MKP-1

expression, and also those which were induced to synthesize lower amounts of MKP-1 upon

addition of a proteasome inhibitor (Orlowski et al., 2002). Of the analyzed sequences, siRNA

constructs targeting the region from nucleotides 106-123 were most active. The corresponding

oligonucleotides were 5'-CGCCGGCCAC-ATCGCCGGCG-AGTACTGGCC-GGCGATGTGG-

CCGGCGTTTT-TT-3' (sense) and 5'-AATTAAAAAA-CGCCGGCCAC-ATCGCCGGCC-

AGTACTCGCC-GGCGATGTGG-CCGGCGGGCC-3' (antisense). As controls, cell lines were

prepared that contained pLPCX and p*Silencer* 1.0-U6 with cloned oligonucleotides that had an

identical nucleotide composition to the siRNA construct, but a scrambled sequence (ss) that was

not complementary to any known genes.

Results

Anthracyclines increase phosphorylation of p44/42-MAPK. To evaluate the impact of

anthracyclines on the p44/42-MAPK pathway in breast epithelium-derived cell lines, A1N4-*myc*

human mammary epithelial cells, and BT-474 and MDA-MB-231 breast carcinoma cells, were

exposed to doxorubicin at 5 μM for 4 hours. This anthracycline induced an increase in dually-

phosphorylated (Thr202/Tyr204), activated p44 and p42 in all three cell lines (Fig. 1A). Total

levels of p44 and p42 were unaffected under these conditions, as were the levels of another

control protein, HSC-70, indicating that doxorubicin indeed changed the phosphorylation status

of ERK-1/2. Under similar conditions, the related anthracycline epirubicin also increased

phospho-ERK-1/2 levels in these cells (Fig. 1B). The anthracycline-enhanced signaling was seen

in the presence of medium containing serum-derived growth factors that stimulate p44/42 (BT-

474 and MDA-MB-231 cells), and even in the presence of medium supplemented with both

serum and EGF (A1N4-*myc* cells). Both anthracyclines induced an increase in phospho-p44/42-

MAPK levels in a time-dependent fashion (Fig. 1C for MDA-MB-231 cells and doxorubicin;

others not shown), with the first evidence of an increase seen at two hours. At four hours

phospho-ERK-1/2 levels reached their maximum, when they were increased by up to 5.9-fold

compared with vehicle controls. Subsequently, the magnitude of the increase declined somewhat,

but phospho-p44/42 levels remained elevated throughout the time course examined. Doxorubicin

and epirubicin also increased phospho-ERK-1/2 levels in a concentration-dependent fashion

(Fig. 1D for MDA-MB-231 cells and epirubicin; doxorubicin not shown), beginning at 0.5 μM.

Further titration of the anthracycline concentration generally led to a plateau, with the maximal

effect being noted in the 2 to 5 μM range.

Induction of phospho-p44/42 is associated with MAPK activation.   In order to determine

if the increased levels of phospho-ERK-1/2 were an indication of enhanced activity of the

p44/42-MAPK pathway, the phosphorylation status of p90 RSK was evaluated. Activation of the

downstream target p90 RSK occurs by ERK-mediated phosphorylation at residues Thr359 and

Ser363 (Dalby et al., 1998). Treatment of A1N4-*myc*, BT-474, and MDA-MB-231 cells with

doxorubicin (Fig. 2A) or epirubicin (Fig. 2B) resulted in increased levels of dually-

phosphorylated (Thr359/Ser363) RSK-1 in all three cell lines compared with controls that

received fresh medium containing serum and vehicle only. Since activated RSK phosphorylates

the downstream target Bad at Ser112 (Bonni et al., 1999), this protein's phosphorylation status

was then studied. As for p44/42 and RSK-1, phospho-Ser112-Bad levels increased in all three

cell lines after treatment with doxorubicin (Fig. 2A) or epirubicin (Fig. 2B). RSK and Bad

phosphorylation was enhanced without any changes in either total ERK-1/2 (Fig. 1A,B), or in

total RSK, Bad, or HSC-70 levels (Fig. 2A,B). These effects of doxorubicin occurred in a time-

dependent manner, but were somewhat delayed compared with that for phospho-p44/42-MAPK.

While ERK phosphorylation peaked at 4 hours (Fig. 1C), the increase in phospho-RSK, which

peaked at an up to 4.9-fold increase, occurred at 6 hours (Fig. 2C), and for phospho-BAD this

occurred at 8 hours, when Bad phosphorylation was increased by up to 2.7-fold (Fig. 2C).

Phospho-RSK and phospho-Bad also increased in a manner that was dependent on the

concentration of doxorubicin (not shown). These results support the conclusion that

anthracyclines enhanced not only the phosphorylation of ERK-1/2, but also the activity of this

pathway as evidenced by increased levels of the phosphorylated forms of downstream target

proteins.

MAPK activation is anti-apoptotic. The p44/42-MAPK pathway plays a role in

apoptosis, and its activation generally results in an increase in the threshold for cell death (Dent

and Grant, 2001). It was therefore of interest to examine the possibility that the anthracycline-

induced increase in phospho-ERK-1/2 was anti-apoptotic in breast-derived epithelial cells. To

evaluate the impact of stimulation of p44/42-MAPK, cells were treated with anthracycline either

in the presence of EGF, which activated ERK-1/2 phosphorylation (not shown), or in its absence.

For all three cell lines both anthracyclines induced less apoptosis in the presence of EGF. In the

case of epirubicin, for example, EGF reduced the induction of apoptosis by 40% in A1N4-*myc*

and BT-474 cells, and by 54% in MDA-MB-231 cells (Table I). EGF can also activate other anti-

apoptotic pathways in some breast cancer cells, however, such as the protein kinase B/Akt

serine/threonine kinase (Mao et al., 2000). Cell lines expressing the dominant positive D319N

ERK-2 sevenmaker mutant were therefore prepared and treated with vehicle or anthracycline.

Expression of this dominant-positive allele in A1N4-*myc* cells inhibited apoptosis by 62% when

these were treated with epirubicin compared with vector-containing controls, and by 39% and

45% in BT-474 and MDA-MB-231 cells, respectively (Table I). This finding supports the

hypothesis that activation of signaling through p44/42-MAPK by anthracyclines is anti-

apoptotic.

Anthracyclines decrease expression of MKP-1. Activation of the p44/42-MAPK pathway by

anthracyclines has previously been described to occur as a result of effects on the upstream

kinases, which can be blocked by inhibitors of the MAPK kinase MEK. Evaluation of A1N4-

myc, BT-474, and MDA-MB-231 cells did occasionally reveal a modest increase in dually

phosphorylated (Ser217/Ser221) MEK, but this was not consistently seen either at 4 hours (Fig. 3

A,B) or in time course experiments (not shown), suggesting a contribution from another

mechanism. To further investigate a possible role for upstream events, cells were preincubated

with the MEK inhibitor PD 98059 at 25 and also 100 μM for 1 hour (Fig. 3C). While this agent

decreased overall p44/42-MAPK phosphorylation, subsequent treatment with doxorubicin still

resulted in higher levels of phospho-ERK-1/2 compared with controls. Experiments with the

structurally unrelated MEK inhibitor U0126 yielded comparable results (not shown). Cellular

MAPK activity is also modulated through the action of protein phosphatases, including both

phosphoprotein phosphatase-2A (PP2A) and -1 (PP1) (reviewed by Camps et al., 2000; English

et al., 1999). To determine if these might be involved, cells were preincubated either with

okadaic acid (OA) alone at concentrations that would inactivate both PP2A and PP1, or okadaic

acid in combination with PD 98059 (Fig. 3D). Doxorubicin was able to enhance phospho-ERK-

1/2 levels under all of these conditions, suggesting that inhibition of either PP1, PP2A, or both

played no role in this process.

Another group of phosphatases that impact upon p44/42-MAPK activity are the dual

specificity phosphatases (English et al., 1999; Camps et al., 2000). Since MKP-1 has been

reported to be overexpressed in a high proportion of breast carcinomas (Loda et al., 1996), the

impact of anthracyclines on this phosphatase was evaluated. In A1N4-*myc*, BT-474, and MDA-

MB-231 cells treated with doxorubicin, absolute MKP-1 levels declined sharply (Fig. 4A). This

occurred in a manner that was dependent on both the anthracycline concentration (not shown), as

well as on time (Fig. 4B). In regards to the latter, decreased levels of MKP-1 were seen as early

as 2 hours, a time at which p44/42 phosphorylation was just beginning to increase (Fig. 1C).

The anthracycline concentrations used in these studies were representative of peak

plasma concentrations achieved in patients undergoing chemotherapy (Greene et al., 1983),

suggesting that such effects could also occur *in vivo*. To further evaluate this possibility, a

murine xenograft model of human breast carcinoma using BT-474 cells was used, and tumor-

bearing mice were treated with a single dose of liposomal doxorubicin. Immunofluorescence

studies of tumor tissue harvested 24-hours later showed that the abundance of phospho-ERK-1/2

was increased by this anthracycline (Fig. 5B) when compared with vehicle treated controls (Fig.

5A). In contrast, while MKP-1 protein was detectable in control xenograft tissue (Fig. 5C), after

treatment with doxorubicin its expression levels were decreased (Fig. 5D). These results support

the hypothesis that the ability of anthracyclines to repress MKP-1 and enhance phospho-ERK-

1/2 is seen both *in vitro* and *in vivo*.

Anthracyclines decrease MKP-1 transcription.   The ability of anthracyclines such as

doxorubicin to specifically decrease expression of genes, including α-actin, myosin light chain,

and muscle creatine kinase in cardiac and skeletal muscles (Ito et al., 1990), suggested the

possibility that MKP-1 expression might be impacted at a transcriptional level. When RT-PCR

was used to evaluate the levels of MKP-1 mRNA after treatment with doxorubicin in a semi-

quantitative fashion, the abundance of these transcripts was indeed decreased in all three cell

lines when compared with GAPDH (Fig. 6A). By densitometry, messenger levels were

decreased in A1N4-*myc*, BT-474, and MDA-MB-231 cells to $80 \pm 9\%$, $65 \pm 5\%$, and $72 \pm 10\%$

of baseline, respectively ($P<0.03$)(Fig. 6B). This occurred in parallel with a decreased abundance

of *c-myc* mRNA, which is known to be repressed after doxorubicin treatment. To evaluate the

impact on MKP-1 mRNA in a more quantitative fashion, and to determine if decreased

transcription from the MKP-1 promoter contributed to the decline in MKP-1 mRNA, cell lines

harboring an MKP-1 promoter-luc reporter construct were treated with doxorubicin or

epirubicin. Neither anthracycline induced a decrease in luciferase activity from a control CMV-luc vector, but both repressed absolute (not shown), as well as relative luciferase activity from the MKP-1-luc construct (Fig. 6C). With respect to the latter, doxorubicin decreased relative activity to $62 \pm 16\%$ of baseline ($P<0.02$), while epirubicin did so to $53 \pm 15\%$ of baseline ($P<0.03$).

Down-regulation of MKP-1 blunts activation of p44/42-MAPK. To more directly evaluate the role of MKP-1 repression in anthracycline-mediated activation of p44/42 MAPK, cell lines were constructed that stably expressed the Q3 small interfering RNA directed against MKP-1. siRNA expressing cells had lower basal levels of MKP-1 expression compared with cells expressing a control scrambled sequence (ss) small interfering RNA. In addition, when exposed to proteasome inhibitors that induce MKP-1 (Orlowski et al., 2002), the levels of MKP-1 expressed were lower in the siRNA-expressing cells (not shown). BT-474/Q3 ssRNA control cells treated with doxorubicin had higher levels of phospho-ERK-1/2 (Fig. 7A), as had been the case for parental BT-474 cells (Fig. 1A). However, BT-474/Q3 siRNA cells had lower levels of phospho-p44/42 MAPK after treatment with doxorubicin. As an additional test of this hypothesis, mouse embryo fibroblasts derived from MKP-1 knockout mice (Dorfman et al., 1996) were examined, and compared with control MEFs. After treatment with doxorubicin the wild-type MKP-1 +/+ MEFs had increased levels of phospho-p44/42 (Fig. 7B). Activation of p44/42 MAPK in MKP-1 heterozygote (+/-) knockout cells was decreased compared with wild-type, however, while activation in homozygous (-/-) MKP-1 knockout cells was almost undetectable (Fig. 7B). Since cells with decreased (Fig. 7A) or absent (Fig. 7B) MKP-1 had

blunted levels of phospho-ERK-1/2 after doxorubicin treatment, these findings support the

hypothesis that anthracyclines activate p44/42 in part by repressing MKP-1.

Discussion

Some of the more ubiquitous cellular signal transduction cascades are the MAPK pathways, including p44/42-MAPK, which plays important roles in cell development, growth, differentiation, and apoptosis (Dent et al., 1998; Schaeffer and Weber, 1999; Cross et al., 2000). With respect to the latter, activation of ERK-1/2 generally results in an increase in the threshold for cell death (Dent and Grant, 2001). The anthracyclines are chemotherapeutics that have been described in some models to activate p44/42-MAPK, including in primary rat ventricular myocytes (Adderley and Fitzgerald, 1999; Zhu et al., 1999), SK-N-SH neuroblastoma cells (Guise et al., 2001), H4IIE rat hepatoma cells (Kim et al., 2001), SiHa human cervical carcinoma cells (Yeh et al., 2002), and U937 monoblasts (Mas et al., 2003). In other cells, however, including the H9 human T-cell leukemia line (Yu et al., 1996) and human KB-3 human epidermal carcinoma cells (Stone and Chambers, 2000), ERK was not activated. Such activation is of interest in that it may inhibit the ability of anthracyclines to induce apoptosis, and we therefore sought to examine the effects of doxorubicin and epirubicin on breast epithelium-derived and carcinoma cell lines, where this has not been well studied. Both anthracyclines were noted to increase the levels of phospho-ERK-1/2 in a time- and concentration-dependent manner (Fig. 1). This was associated with enhanced activity of the p44/42-MAPK pathway, in that there was increased phosphorylation of the direct downstream MAPK target p90 RSK-1, and also of Bad (Fig. 2), whose phosphorylation in part is impacted upon by RSK. Since Bad phosphorylation at Ser112 is anti-apoptotic through its inability to associate with $Bcl-x_L$, the possibility was considered that activation of p44/42 provided the breast-derived cells with survival signals. Consistent with this possibility, stimulation of p44/42 with EGF or a constitutively active ERK-2 construct inhibited apoptosis (Table I).

Though anthracyclines are active agents in the treatment of breast cancer, many patients do not have complete responses, while others suffer relapses after chemotherapy. Novel combination regimens that would enhance the ability of anthracyclines to induce apoptosis of cancer cells could, therefore, improve the prognosis of breast cancer patients. The finding that stimulation of the p44/42 pathway decreases anthracycline-mediated apoptosis suggests that inhibition of p44/42, such as by targeting MEK, may enhance doxorubicin- and epirubicin-mediated programmed cell death. Indeed, preliminary investigations have shown that PD 98059 and U0126 can enhance doxorubicin- and epirubicin-mediated apoptosis in these three cell lines (not shown). One important consideration would be the known potential cardiac toxicity of anthracyclines, which often limits their clinical applications. Since blockade of MEK in primary rat ventricular myocytes enhances apoptosis (Zhu et al., 1999), while an MEK inhibitor/anthracycline combination could have enhanced anti-tumor activity, it might also increase myofibrillar damage. In this regard, it is interesting to note that combination regimens containing anthracyclines and trastuzumab, an anti-HER-2/neu monoclonal antibody that in part decreases activation of p44/42 through upstream effects, have been reported to have enhanced cardiac toxicity (reviewed by Sparano, 2001).

Activation of p44/42-MAPK by anthracyclines has been attributed to the induction of oxygen free radicals, which then stimulate upstream kinases including Ras, Raf, and MEK. While we could demonstrate modest MEK activation this was not a consistent finding (Fig. 3), suggesting that another mechanism could be involved. The ability of anthracyclines to decrease MKP-1 protein levels *in vitro* and *in vivo* (Figs. 4 and 5), and MKP-1 mRNA and promoter function (Fig. 6), implicated this activity as a possibility. Additional findings that cells with decreased MKP-1 due to expression of siRNAs, and fibroblasts from MKP-1 knockout mice

treated with anthracyclines had lower levels of phospho-ERK (Fig. 7) strongly support the

hypothesis that down-regulation of MKP-1 by anthracyclines is a significant contributor to

preservation of phospho-p44/42 levels. Our results do not rule out the possibility, however, that

other mechanisms may impact on this process as well. For example, anthracyclines could

stimulate proteasome-mediated degradation of MKP-1, which is known to be subject to

proteolysis through this pathway (Brondello et al., 1999; Orlowski et al., 2002). In that

anthracyclines such as aclarubicin seem to inhibit the proteasome (Isoe et al., 1992) this may

seem less likely. However, in myelomonocytic leukemia cells anthracyclines stimulate

proteasome activity (Ciftci et al., 2001), and this possible mechanism may therefore be worthy of

further study. Also, since MKP-1 is one of a family of dual specificity phosphatases involved in

the control of p44/42 activity, the possibility that anthracyclines may also impact on the

expression of other family members would merit consideration. In this regard, we have found

evidence in preliminary studies that MKP-2 expression is decreased by doxorubicin as well (not

shown). It is interesting to note that, while the impact of other agents on both MKP-1 and ERK-

1/2 has not been widely studied, proteasome inhibitors have the opposite effect of anthracyclines,

in that they transcriptionally induce MKP-1 and decrease ERK-1/2 activity (Orlowski et al.,

2002). Thus, repression of MKP-1 resulting in increased phosphorylation of p44/42-MAPK may

be a mechanism unique to anthracyclines.

The ability of anthracyclines to specifically impact upon gene expression is a well known

property of this class of compounds. Acute doxorubicin toxicity is associated with changes in

cardiac-specific gene expression, with suppression of muscle-specific genes including α-actin,

myosin light chain, and muscle creatine kinase (Ito et al., 1990; Torti et al., 1998), as well as

suppression of the mitochondrial iron sulfur protein, phosphofructokinase, and ATP/ADP

translocase (Jeyaseelan et al., 1997). Several studies have documented that transcription of the

gene CARP is repressed by doxorubicin in neonatal rat cardiac myocytes (Jeyaseelan et al.,

1997). Mechanistic investigations revealed that this downregulation is not due to p44/42-MAPK

activation, but rather seems to depend on an H7-sensitive serine/threonine kinase (Aihara et al.,

2000). Doxorubicin has also been shown to inhibit ventricular myocyte sarco(endo)plasmic

reticulum Ca^{2+}-ATPase 2 by stimulating expression of the transcription factor Egr-1 (Arai et al.,

2000). One of these pathways may be involved in doxorubicin's suppression of MKP-1

transcription, although we were unable to document enhanced Egr-1 transcription by RT-PCR

(not shown). Additional studies will be needed to further delineate the mechanism by which

anthracyclines specifically repress MKP-1.

Acknowledgements

References

Adderley SR and Fitzgerald DJ (1999) Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. *J Biol Chem* **274:**5038-5046.

Aihara Y, Kurabayashi M, Tanaka T, Takeda SI, Tomaru K, Sekiguchi KI, Ohyama Y, and Nagai R (2000) Doxorubicin represses CARP gene transcription through the generation of oxidative stress in neonatal rat cardiac myocytes: possible role of serine/threonine kinase-dependent pathways. *J Mol Cell Cardiol* **32:**1401-1414.

Arai M., Yoguchi A, Takizawa T, Yokoyama T, Kanda T, Kurabayashi M, and Nagai R (2000) Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription. *Circ Res* **86:**8-14.

Bonni A, Brunet A, West AE, Datta SR, Takasu MA, and Greenberg ME (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. *Science* **286:**1358-1362.

Brondello JM, Pouyssegur J, and McKenzie FR (1999) Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. *Science* **286:**2514-2517.

Camps M, Nichols A, and Arkinstall S (2000) Dual specificity phosphatases: a gene family for control of MAP kinase function. *FASEB J* **14:**6-16.

Ciftci O, Ullrich O, Schmidt CA, Diestel A, and Hass R (2001) Regulation of the nuclear proteasome activity in myelomonocytic human leukemia cells after adriamycin treatment. *Blood* **97:**2830-2838.

Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, and Lord JM (2000) Serine/threonine protein kinases and apoptosis. *Exp Cell Res* **256:**34-41.

Dalby KN, Morrice N, Caudwell FB, Avruch J, and Cohen P (1998) Identification of regulatory

phosphorylation sites in mitogen-activated protein kinase (MAPK)-activated protein kinase-

1a/p90rsk that are inducible by MAPK. *J Biol Chem* **273:**1496-1505.

Dent P and Grant S (2001) Pharmacologic interruption of the mitogen-activated extracellular-

regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role

in promoting cytotoxic drug action. *Clin Cancer Res* **7:**775-783.

Dent P, Jarvis WD, Birrer MJ, Fisher PB, Schmidt-Ullrich RK, and Grant S (1998) The roles of

signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route

to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and

loss of clonogenicity. *Leukemia* **12:**1843-1850.

Dickson RB and Lippman ME (1995) Growth factors in breast cancer. *Endocr Rev* **16:**559-589.

Dorfman K, Carrasco D, Gruda M, Ryan C, Lira SA, and Bravo R (1996) Disruption of the

erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in

ERP/MKP-1-deficient fibroblasts. *Oncogene* **13:**925-931.

English J, Pearson G, Wilsbacher J, Swantek J, Karandikar M, Xu S, and Cobb MH (1999) New

insights into the control of MAP kinase pathways. *Exp Cell Res* **253:**255-270.

Greene RF, Collins JM, Jenkins JF, Speyer JL, and Myers CE (1983) Plasma pharmacokinetics

of adriamycin and adriamycinol: implications for the design of *in vitro* experiments and

treatment protocols. *Cancer Res* **43:**3417-3421.

Guise S, Braguer D, Carles G, Delacourte A, and Briand C (2001). Hyperphosphorylation of tau

is mediated by ERK activation during anticancer drug-induced apoptosis in neuroblastoma

cells. *J Neurosci Res* **63:**257-267.

Isoe T, Naito M, Shirai A, Hirai R, and Tsuruo T (1992) Inhibition of different steps of the ubiquitin system by cisplatin and aclarubicin. *Biochim Biophys Acta* **1117:**131-135.

Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, Wade R, Gahlmann R, Lyons G, Kedes L, and Torti FM (1990) Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells *in vivo* and *in vitro*. *Proc Natl Acad Sci USA* **87:**4275-4279.

Jeyaseelan R, Poizat C, Baker RK, Abdishoo S, Isterabadi LB, Lyons GE, and Kedes L (1997) A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes. *J Biol Chem* **272:**22800-22808.

Jeyaseelan R, Poizat C, Wu HY, and Kedes L (1997) Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. *J Biol Chem* **272:**5828-5832.

Kim SG, Sung M, Kang KW, Kim SH, Son MH, and Kim WB (2001) DA-125, a novel anthracycline derivative showing high-affinity DNA binding and topoisomerase II inhibitory activities, exerts cytotoxicity via c-Jun N-terminal kinase pathway. *Cancer Chemother Pharmacol* **47:**511-518.

Kojima S, Yanagihara I, Kono G, Sugahara T, Nasu H, Kijima M, Hattori A, Kodama T, Nagayama KI, and Honda T (2000) mkp-1 encoding mitogen-activated protein kinase phosphatase 1, a verotoxin 1 responsive gene, detected by differential display reverse transcription-PCR in Caco-2 cells. *Infect Immun* **68:**2791-2796.

Li J, Gorospe M, Hutter D, Barnes J, Keyse SM, and Liu Y (2001) Transcriptional induction of MKP-1 in response to stress is associated with histone H3 phosphorylation-acetylation. *Mol Cell Biol* **21:**8213-8224.

Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, Wang Y, Magi-Galluzzi C, and
Stork PJ (1996) Expression of mitogen-activated protein kinase phosphatase-1 in the early
phases of human epithelial carcinogenesis. *Am J Pathol* **149:**1553-1564.

Mao M, Fang X, Lu Y, Lapushin R, Bast RCJr, and Mills GB (2000) Inhibition of growth-factor-
induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C
in breast cancer cells. *Biochem J* **352Pt 2:**475-482.

Mas VM, Hernandez H, Plo I, Bezombes C, Maestre N, Quillet-Mary A, Filomenko R, Demur
C, Jaffrezou JP, and Laurent G (2003) Protein kinase Czeta mediated Raf-1/extracellular-
regulated kinase activation by daunorubicin. *Blood* **101:**1543-1550.

Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, and Eppenberger U (2000)
Potential prognostic value of mitogen-activated protein kinase activity for disease-free
survival of primary breast cancer patients. *Int J Cancer* **89:**384-388.

Orlowski RZ. and Baldwin AS (2002) NF-kappaB as a therapeutic target in cancer. *Trends Mol
Med* **8:**385-389.

Orlowski RZ, Small GW, and Shi YY (2002) Evidence that inhibition of p44/42 mitogen-
activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. *J
Biol Chem* **277:**27864-27871.

Schaeffer HJ and Weber M.J (1999) Mitogen-activated protein kinases: specific messages from
ubiquitous messengers. *Mol Cell Biol* **19:**2435-4244.

Scheid MP, Schubert KM, and Duronio V (1999) Regulation of bad phosphorylation and
association with Bcl-x(L) by the MAPK/Erk kinase. *J Biol Chem* **274:**31108-31113.

Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, and Orlowski RZ (2002) Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. *Cancer Res* **62:**3868-3875.

Sparano JA (2001) Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. *Semin Oncol* **28:**20-27.

Stone AA and Chambers TC (2000) Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. *Exp Cell Res* **254:**110-119.

Torti SV, Akimoto H, Lin K, Billingham ME, and Torti FM (1998) Selective inhibition of muscle gene expression by oxidative stress in cardiac cells. *J Mol Cell Cardiol* **30:**1173-1180.

Yeh PY, Chuang SE, Yeh KH, Song YC, and Cheng AL (2001) Nuclear extracellular signal-regulated kinase 2 phosphorylates p53 at Thr55 in response to doxorubicin. *Biochem Biophys Res Commun* **284:**880-886.

Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK, and Cheng AL (2002) Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. *Biochem Pharmacol* **63:**1423-1430.

Yu R, Shtil AA, Tan TH, Roninson IB, and Kong AN (1996) Adriamycin activates c-jun N-terminal kinase in human leukemia cells: a relevance to apoptosis. *Cancer Lett* **107:**73-81.

Zhu W, Zou Y, Aikawa R, Harada K, Kudoh S, Uozumi H, Hayashi D, Gu Y, Yamazaki T, Nagai R, Yazaki Y, and Komuro I (1999) MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes. *Circulation* **100:**2100-2107.

Footnotes

* Current address: University of Houston-Victoria, School of Arts and Science, 3007 N. Ben Wilson, Victoria, TX 77901-5731

Figure Legends

FIG. 1. Phospho-p44/42-MAPK in cells exposed to anthracyclines.

A. A1N4-*myc*, BT-474, or MDA-MB-231 cells were exposed to vehicle (-) or to 5 μM
doxorubicin (+), in complete medium containing fetal calf serum (all cell lines) or serum
supplemented with EGF (A1N4-*myc* cells) for 4 hours. The impact on p44/42-MAPK
signaling was evaluated by Western blotting using antibodies directed against the dually
phosphorylated (Thr202/Tyr204), activated forms of ERK-1 and –2. Equal loading was
confirmed by reprobing with antibodies that recognized ERK in a phosphorylation status-
independent manner, and then with antibodies directed against HSC-70. All of the panels in
this figure depict one representative result of two independent experiments.

B. A1N4-*myc*, BT-474, or MDA-MB-231 cells were exposed to vehicle or epirubicin at 5 μM for
4 hours and analyzed as in panel A above.

C. MDA-MB-231 cells were exposed either to vehicle or to doxorubicin at 5 μM for the
indicated time periods. The fold increase in phospho-MAPK abundance is shown in relation
to vehicle-treated cells, and is adjusted for loading of ERK.

D. MDA-MB-231 cells were exposed to the indicated concentrations of epirubicin for four
hours, and phospho-ERK-1/2 levels were analyzed.

FIG. 2. Phospho-RSK and –Bad in cells exposed to anthracyclines.

A. A1N4-*myc*, BT-474, or MDA-MB-231 cells were exposed to vehicle (-) or to doxorubicin (+)
at 5 μM for 4 hours. The impact on phospho-RSK (Thr359/Ser363) and phospho-Bad
(Ser112) levels was evaluated by Western blotting using antibodies directed against the
indicated phospho-proteins. Equal loading was confirmed by reprobing with RSK and Bad

antibodies that recognize these proteins in a phosphorylation state independent manner, and also with HSC-70 antibodies. All of the panels in this figure depict one representative result of two independent experiments.

B. A1N4-*myc*, BT-474, or MDA-MB-231 cells were exposed to vehicle (-) or to epirubicin (+) at 5 μM for 4 hours, and analyzed as in panel A above.

C. MDA-MB-231 cells were exposed either to vehicle or to doxorubicin at 5 μM for the indicated time periods. The impact on phospho-RSK (Thr359/Ser363) and phospho-Bad (Ser112) was evaluated as above. For phospho-RSK and phospho-Bad the fold increase in phosphorylated proteins is shown in relation to vehicle-treated cells, and is adjusted for loading of HSC-70.

FIG. 3. Effects of anthracyclines on factors upstream of ERK.

A. A1N4-*myc*, BT-474, or MDA-MB-231 cells were exposed to vehicle (-) or to doxorubicin (+) at 5 μM for 4 hours. The impact on phospho-MEK was evaluated by Western blotting using antibodies directed against the dually phosphorylated (Ser217/Ser221) protein. Equal loading was confirmed by reprobing with antibodies that recognize MEK in a phosphorylation status-independent manner. The fold increase in phospho-MEK abundance is shown in relation to vehicle-treated cells, and is adjusted for loading of MEK. All of the panels in this figure depict one representative result of two independent experiments.

B. A1N4-*myc*, BT-474, or MDA-MB-231 cells were exposed to vehicle (-) or to epirubicin (+) at 5 μM for 4 hours, and the impact on phospho-MEK was evaluated as in panel A above.

C. MDA-MB-231 cells were pre-treated with vehicle, or PD 98059 at either 25 or 100 μM for 1 hour. They were then treated either with vehicle or doxorubicin at 5 μM for 4 hours. The impact on p44/42-MAPK signaling was evaluated by Western blotting.

D. MDA-MB-231 were preincubated either with vehicle, 25 μM PD 98059, 30 μM okadaic acid (OA), or both (OA+PD) for 1 hour. They were then treated either with vehicle or doxorubicin at 5 μM for 4 hours, and the phospho-ERK-1/2 content was analyzed by Western blotting.

FIG. 4. MKP expression in cells treated with anthracyclines.

A. A1N4-*myc*, BT-474, or MDA-MB-231 cells were exposed to vehicle (-) or to 5 μM doxorubicin (+) for 4 hours. The impact on MKP-1 expression was assayed by Western blotting, and loading was confirmed by stripping and reprobing with HSC-70 antibodies. In addition to MKP-1, which is identified by the arrowhead, the polyclonal antibody used also detects a second, larger molecular weight non-specific protein in MDA-MB-231 cells, which is indicated with an asterisk. All panels in this figure are representative results from one of two independent experiments.

B. MDA-MB-231 cells were exposed to vehicle or to 5 μM doxorubicin for the indicated time periods, and the impact on MKP-1 expression was analyzed by Western blotting. MKP-1 and the cross-reacting protein detected in MDA-MB-231 cells are labeled as indicated above.

FIG. 5. Effect of anthracyclines on *in vivo* phospho-ERK and MKP-1 expression.

A. Immunodeficient nu/nu mice bearing tumor xenografts induced by subcutaneous injection of BT-474 breast carcinoma cells were treated with vehicle. Twenty four hours later tumor tissue was obtained, and evaluated for p44/42-MAPK activation status by

immunofluorescence. Phospho-ERK-1/2 appears as red fluorescence, while the background

blue is a DAPI nuclear stain. All panels in this figure are representative results from one of

two experiments.

B. Immunodeficient nu/nu mice bearing the BT-474-based xenograft were treated with liposomal

doxorubicin (Doxil®), and tumor tissue was analyzed for p44/42-MAPK activation status as

indicated above.

C. Expression of MKP-1 in tumor tissue from vehicle-treated mice was analyzed by

immunofluorescence. MKP-1 was detected as green fluorescence.

D. MKP-1 expression in tumor tissue from doxorubicin-treated mice was analyzed as indicated

above.

FIG. 6. Impact of anthracyclines on MKP-1 mRNA abundance and promoter function.

A. A1N4-*myc*, BT-474, or MDA-MB-231 cells were exposed to vehicle (-), or to 5 μM

doxorubicin (+) for 4 hours. Total RNA was isolated, and MKP-1, *c-myc*, and GAPDH

messenger RNA expression was evaluated by semi-quantitative RT-PCR, with products

separated by non-denaturing PAGE. This panel shows a representative result from one of

three independent experiments.

B. The abundance of MKP-1 and *c-myc* mRNA detected as described above was determined by

densitometry, and is expressed in relation to GAPDH, which was arbitrarily set at 100. The

results are depicted as the mean ± standard error of the mean from three independent

experiments.

C. BT-474 cells stably transfected either with a plasmid containing an MKP-1 promoter-

luciferase reporter construct, or a control CMV promoter-luciferase reporter construct, were

treated with vehicle, doxorubicin, or epirubicin, with the latter two both at 5 μM for 4 hours.

Luciferase activity was determined for each condition, and expressed as a relative reporter

activity to vehicle, which was arbitrarily set at 100. MKP-1-luc was then normalized to

CMV-luc, and the mean of this ratio is depicted in the graph, along with the standard error of

the mean from four independent experiments.

FIG. 7. Impact of decreased MKP-1 expression on activation of p44/42 by anthracyclines.

A. BT-474-based cell lines stably expressing either the Q3 siRNA to MKP-1, or an RNA with

the same nucleotide composition but a scrambled sequence, were treated with vehicle or 5

μM doxorubicin for 4 hours, and phospho-ERK levels were evaluated by Western blotting.

Total ERK levels are shown as loading controls. Each panel in this figure shows

representative results from one of two independent experiments.

B. Wild-type (MKP-1 +/+) MEFs, as well as heterozygote knockout (MKP-1 +/-) and

homozygote knockout (MKP-1 -/-) MEFs, were treated either with vehicle or 5 μM

doxorubicin for 4 hours, and phospho-ERK levels were evaluated by Western blotting. The

genotype of these cells was confirmed by Southern blotting (data not shown).

Table I

Stimulation of p44/42-MAPK and apoptosis*

Stimulation with EGF

Condition	Cells		
	A1N4-*myc*	BT-474	MDA-MB-231
Epirubicin	1.00	1.00	1.00
Epi + EGF	0.60 ± 0.07 (4)	0.60 ± 0.06 (2)	0.46 ± 0.01 (2)

Stimulation with dominant–positive ERK-2 constructs

Condition	Cells[‡]		
	A1N4-*myc*/ pLPCX	BT-474/ pLPCX	MDA-MB-231/ pLPCX
Epirubicin	1.00	1.00	1.00
	A1N4-*myc*/ pLPCX-CA-ERK-2	BT-474/ pLPCX-CA-ERK-2	MDA-MB-231/ pLPCX-CA-ERK-2
Epirubicin	0.38 ± 0.07 (7)	0.61 ± 0.09 (7)	0.55 ± 0.10 (7)

*The mean fold apoptosis ± standard error of the mean is shown, compared with the controls, which were arbitrarily set at 1.00; the number of determinations is shown in parentheses

[‡]Abbreviations: CA, constitutively active

A

B


C

D

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7